As per reports coming in an interim analysis of a Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results.
Efficacy of Sputnik V against COVID-19 was reported at 91.6% as per Russian Direct Investment Fund.
Kirill Dmitriev, Russian Direct Investment Fund Speaking to ANI has said that India is key partner in terms of production of vaccine.
The Russian counterpart expect that there will be restricted emergency use order for Sputnik V vaccine this month or next.
After that Kirill has said that it will be able to start our vaccine delivery to India.
No comments:
Post a Comment